1. Home
  2. WNW vs HCWB Comparison

WNW vs HCWB Comparison

Compare WNW & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Meiwu Technology Company Limited

WNW

Meiwu Technology Company Limited

HOLD

Current Price

$4.30

Market Cap

3.6M

ML Signal

HOLD

Logo HCW Biologics Inc.

HCWB

HCW Biologics Inc.

HOLD

Current Price

$0.47

Market Cap

3.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WNW
HCWB
Founded
2015
2018
Country
China
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6M
3.0M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
WNW
HCWB
Price
$4.30
$0.47
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$35.00
AVG Volume (30 Days)
3.0M
717.6K
Earning Date
05-12-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$4,099,750.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.14
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.05
$0.25
52 Week High
$13.52
$17.80

Technical Indicators

Market Signals
Indicator
WNW
HCWB
Relative Strength Index (RSI) 61.60 53.19
Support Level $1.27 $0.25
Resistance Level $5.43 $0.78
Average True Range (ATR) 0.93 0.05
MACD -0.11 0.02
Stochastic Oscillator 43.65 93.56

Price Performance

Historical Comparison
WNW
HCWB

About WNW Meiwu Technology Company Limited

Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments including Clean Food platform, Skincare products & service and Technical Service. The company generates the majority of its revenue from Technical services.

About HCWB HCW Biologics Inc.

HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.

Share on Social Networks: